Paul Hastings Sells Shares of NKTX $NKTX
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Paul Hastings, Chief Executive Officer at Nkarta, Inc. ($NKTX), sold 1,776 shares at an average price of $2.71, for a total transaction of $4,812.96. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Nkarta, Inc. Stock Up 1.1%
Shares of Nkarta, Inc. ($NKTX) traded around $2.79 on Tuesday, up 1.1% for the day.
Nkarta, Inc. Earnings
Analysts Set New Price Targets
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Get Nkarta, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NKTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.